EPISODE · Jul 12, 2013 · 11 MIN
A Clear Answer to the Wrong Question
from Journal of Clinical Oncology (JCO) Podcast
The AVAPERL trial reveals a significant improvement in progression-free survival with the combination of pemetrexed/bevacizumab compared with bevacizumab alone as maintenance therapy for advanced non- small-cell lung cancer, but the clinically relevant endpoint remains overall survival.
NOW PLAYING
A Clear Answer to the Wrong Question
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m